<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518219</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-0702</org_study_id>
    <nct_id>NCT00518219</nct_id>
  </id_info>
  <brief_title>To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)</brief_title>
  <official_title>To Compare the Efficacy and Safety of TW vs Valsartan in the MN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment
      of heavy proteinuria of membranous nephropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF.

      Tripterygium (TW) is a Chinese traditional patent drugs, it can reduce proteinuria of chronic
      glomerular nephritis,such as IgA nephropathy. So, we designed this randomized, prospective
      clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of
      heavy proteinuria of MN.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of membranous nephropathy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety and tolerability of TW vs ARB in treatment of MN</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>immunosuppressor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TW 120mg/dï¼ŒValsartan,160mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TW</intervention_name>
    <description>TW,120mg/d</description>
    <arm_group_label>immunosuppressor</arm_group_label>
    <other_name>TW,Tripterygium wilfordii Hook.f</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven idiopathic membranous nephropathy

          -  Nephrotic syndrome with proteinuria (&gt; 4 g/day) and serum albumin &lt; 30 g/dl

          -  Age over 18 with informed consent

        Exclusion Criteria:

          -  Patient with abnormal liver function tests

          -  Prior therapy with sirolimus, CSA, MMF, tacrolimus or azathioprin, chlorambucil,
             levamisole, methotrexate, or nitrogen mustard in the last 90 days,

          -  Active/serious infection,

          -  Patient with hepatitis B surface antigen or who is hepatitis C antibody positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhihong Liu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jinling Hospital, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2007</study_first_submitted>
  <study_first_submitted_qc>August 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name_title>
    <organization>Nanjing University School of Medicine</organization>
  </responsible_party>
  <keyword>TW</keyword>
  <keyword>Valsartan</keyword>
  <keyword>treatment</keyword>
  <keyword>membranous nephropathy</keyword>
  <keyword>proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

